Please use this identifier to cite or link to this item:
Title: Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
Author: Clària i Enrich, Joan
Curto, Anna
Moreau, Richard
Colsch, Benoit
López Vicario, Cristina
Lozano Salvatella, Juan José
Aguilar, Ferran
Castelli, Florence A.
Fenaille, François
Junot, Christophe
Zhang, Ingrid W.
Vinaixa Crevillent, Maria
Yanes, Oscar
Caraceni, Paolo
Trebicka, Jonel
Fernández Gómez, Javier
Angeli, Paolo
Jalan, Rajiv
Arroyo, Vicente
Keywords: Cirrosi hepàtica
Hepatic cirrhosis
Issue Date: Nov-2021
Publisher: Elsevier
Abstract: Background & aims: Acute decompensation (AD) of cirrhosis is a heterogeneous clinical entity associated with moderate mortality. In some patients, this condition develops quickly into the more deadly acute-on-chronic liver failure (ACLF), in which other organs such as the kidneys or brain fail. The aim of this study was to characterize the blood lipidome in a large series of patients with cirrhosis and identify specific signatures associated with AD and ACLF development. Methods: Serum untargeted lipidomics was performed in 561 patients with AD (518 without and 43 with ACLF) (discovery cohort) and in 265 patients with AD (128 without and 137 with ACLF) in whom serum samples were available to perform repeated measurements during the 28-day follow-up (validation cohort). Analyses were also performed in 78 patients with AD included in a therapeutic albumin trial (43 patients with compensated cirrhosis and 29 healthy individuals). Results: The circulating lipid landscape associated with cirrhosis was characterized by a generalized suppression, which was more manifest during AD and in non-surviving patients. By computing discriminating accuracy and the variable importance projection score for each of the 223 annotated lipids, we identified a sphingomyelin fingerprint specific for AD of cirrhosis and a distinct cholesteryl ester and lysophosphatidylcholine fingerprint for ACLF. Liver dysfunction and infections were the principal net contributors to these fingerprints, which were dynamic and interchangeable between patients with AD whose condition worsened to ACLF and those who improved. Notably, blood lysophosphatidylcholine levels increased in these patients after albumin therapy. Conclusions: Our findings provide insights into the lipid landscape associated with decompensation of cirrhosis and ACLF progression and identify unique non-invasive diagnostic biomarkers of advanced cirrhosis. Lay summary: Analysis of lipids in blood from patients with advanced cirrhosis reveals a general suppression of their levels in the circulation of these patients. A specific group of lipids known as sphingomyelins are useful to distinguish between patients with compensated and decompensated cirrhosis. Another group of lipids designated cholesteryl esters further distinguishes patients with decompensated cirrhosis who are at risk of developing organ failures.
Note: Reproducció del document publicat a:
It is part of: Journal of Hepatology, 2021, vol. 75, num. 5, p. 1116-1127
Related resource:
ISSN: 0168-8278
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Biomedicina)

Files in This Item:
File Description SizeFormat 
722356.pdf3.15 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons